Alpha-1, short for Alpha-1 Antitrypsin Deficiency, is a genetic condition where your body doesn’t produce enough of a protective protein called alpha-1 antitrypsin (AAT). This protein is made in the liver and travels through the bloodstream to the lungs, where its job is to shield delicate lung tissue from damage. Without enough of it, the lungs slowly break down over time, and in some cases, the liver itself is harmed too. It’s the most common genetic cause of emphysema and often goes undiagnosed for years because its symptoms mimic other lung conditions.
How the Protein Works
Your immune system sends white blood cells to your lungs constantly, especially when you breathe in irritants like dust or smoke. These white blood cells release a powerful enzyme that breaks down damaged or infected tissue. In a healthy person, AAT acts like a shield, neutralizing that enzyme before it can chew through healthy lung tissue. Think of it as a cleanup crew with a built-in safety switch: the enzyme does its job, then AAT shuts it down.
In people with Alpha-1, there isn’t enough AAT circulating in the blood to keep that enzyme in check. The result is ongoing, unchecked destruction of the tiny air sacs in the lungs. Over time, this leads to emphysema and chronic obstructive pulmonary disease (COPD). The damage also ramps up mucus production and triggers a cycle of inflammation that makes things progressively worse.
Why the Liver Gets Involved
Alpha-1 isn’t purely a lung disease. The root problem starts in the liver, where the AAT protein is manufactured. In the most common severe form of the condition, the liver cells produce a misshapen version of the protein. Instead of being released into the bloodstream, these misfolded proteins clump together into long chains and get stuck inside liver cells. The buildup creates a toxic environment that can scar the liver over time.
About 10% of infants and 15% of adults with Alpha-1 develop liver disease as a result. In severe cases, the accumulated protein triggers cirrhosis, which is permanent scarring that impairs liver function. This is what makes Alpha-1 a two-organ disease: the lungs suffer from not having enough protein, and the liver suffers from having too much of the wrong kind trapped inside it.
Genetics and Inheritance
Alpha-1 is inherited from both parents. Everyone carries two copies of the gene that controls AAT production, one from each parent. The normal version is called M, so a person with two normal copies has the genotype MM and produces healthy levels of the protein (150 to 350 mg/dL in the blood).
The most clinically significant variant is called Z. A person who inherits two Z copies (ZZ genotype) has the most severe form of the deficiency, with blood levels typically between just 20 and 45 mg/dL. This is the genotype most strongly linked to early-onset emphysema and liver disease. If you inherit one normal copy and one Z copy (MZ genotype), your levels fall in a middle range of about 90 to 210 mg/dL. MZ carriers generally have a lower risk, but that risk rises significantly if they smoke. Another variant called S exists, but people with the MS genotype tend to have near-normal protein levels and don’t appear to face increased COPD risk when smoking history is accounted for.
Because Alpha-1 is co-dominant, both gene copies contribute to how much functional protein you produce. You don’t need to be ZZ to be affected, but ZZ carriers face the most serious health consequences.
Symptoms to Recognize
Lung symptoms typically appear between ages 30 and 50. The earliest signs often look like garden-variety respiratory problems: shortness of breath during exercise, wheezing, a persistent cough that produces mucus, frequent chest colds, and unusual fatigue. Many people are initially diagnosed with asthma or COPD without anyone investigating the underlying genetic cause.
Liver-related symptoms can appear at any age, including infancy. Warning signs include yellowing of the skin and eyes, itchy skin, swelling in the legs or abdomen, and vomiting blood. In rare cases, the first sign of Alpha-1 is painful red bumps on the skin called panniculitis, which can move around the body and sometimes leak fluid.
How Smoking Accelerates Damage
Cigarette smoke is uniquely destructive for people with Alpha-1. Smoke does two things at once: it attracts more of those tissue-destroying white blood cells to the lungs, and it chemically disables whatever AAT protein is present. Specifically, compounds in cigarette smoke alter a critical part of the AAT molecule, stripping it of its ability to neutralize the damaging enzyme. Research in Molecular Medicine showed that AAT purified from the blood of active smokers had markedly reduced protective function, regardless of whether the person had Alpha-1 or not.
For someone who already has low AAT levels, this combination is devastating. Smokers with the ZZ genotype develop emphysema much earlier and more severely than nonsmokers with the same genotype. Even MZ carriers who smoke face COPD risk comparable to people with more severe genetic profiles. Avoiding cigarette smoke, including secondhand exposure, is the single most impactful thing someone with Alpha-1 can do to preserve lung function.
Getting Tested
Alpha-1 is widely underdiagnosed. The American Thoracic Society and the European Respiratory Society recommend testing for all patients with COPD or incompletely reversible airflow obstruction. Testing is also recommended for people with unexplained liver disease, a lung condition called bronchiectasis with no known cause, and first-degree relatives of anyone who carries an Alpha-1 variant.
Diagnosis starts with a simple blood test measuring AAT levels. A level below 80 mg/dL supports the diagnosis, though the exact threshold depends on the lab method used. Genetic testing then identifies the specific genotype. Because symptoms overlap so heavily with ordinary COPD and asthma, the average person with Alpha-1 sees multiple doctors over several years before getting the correct diagnosis.
Treatment Options
The cornerstone treatment for Alpha-1 lung disease is called augmentation therapy. It works by infusing purified AAT protein from donated human blood directly into the bloodstream, raising levels above the protective threshold of 80 mg/dL. Infusions are given intravenously once a week. A Cochrane review found that patients receiving augmentation therapy lost lung tissue significantly more slowly than those on placebo, as measured by CT scans of lung density.
Augmentation therapy protects the lungs but does not reverse existing damage, which is why early diagnosis matters. It also doesn’t address liver disease, since the liver problem stems from trapped misfolded proteins rather than a shortage of circulating ones. For severe liver disease, a transplant may ultimately be necessary.
Beyond augmentation, standard COPD management applies: bronchodilators for breathing, pulmonary rehabilitation to improve exercise tolerance, and avoiding lung irritants. Vaccines against flu and pneumonia help prevent infections that can trigger flare-ups.
New Treatments in Development
One of the most promising areas of research targets the liver side of Alpha-1. A therapy called ARO-AAT uses RNA interference, a technique that silences the gene responsible for producing the misfolded Z protein in liver cells. By reducing production of the toxic protein, the goal is to prevent further liver damage. ARO-AAT is administered as a subcutaneous injection and is currently in phase II/III clinical trials enrolling patients with established liver scarring. Earlier attempts at similar approaches were halted due to safety concerns, but the newer delivery method is designed to improve the safety profile significantly.